MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Novartis AG

Fechado

112.41 1.45

Visão Geral

Variação de preço das ações

24h

Atual

Mín

110.38

Máximo

114.32

Indicadores-chave

By Trading Economics

Rendimento

-369M

2.8B

Vendas

386M

14B

P/E

Médio do Setor

18.992

63.778

EPS

1.98

Rendimento de Dividendos

3.47

Margem de lucro

20.8

Funcionários

75,883

EBITDA

-426M

5.2B

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+0.21% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.47%

2.39%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

6.9B

221B

Abertura anterior

110.96

Fecho anterior

112.41

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Novartis AG Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de fev. de 2025, 06:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis to Buy Anthos Therapeutics for Up to $3.08 Billion

31 de jan. de 2025, 09:49 UTC

Ganhos

Novartis Expects Further Profit, Sales Growth Despite Competition Threat -- 2nd Update

31 de jan. de 2025, 08:06 UTC

Ganhos

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales -- Update

31 de jan. de 2025, 06:32 UTC

Ganhos

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales

17 de mar. de 2025, 07:34 UTC

Conversa de Mercado

Novartis Growth Outlook Clouded by Patent Expiries, Pipeline Concerns -- Market Talk

4 de mar. de 2025, 18:45 UTC

Ganhos

Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction -- IBD

11 de fev. de 2025, 09:25 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion -- Update

11 de fev. de 2025, 06:42 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Novartis to Buy Anthos Therapeutics for Up to $3.08 Bln

11 de fev. de 2025, 06:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis: Acquisition Is Aligned With Strategic Focus on Cardiovascular Therapeutic Area

11 de fev. de 2025, 06:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis: Abelacimab's Lead Indication Is Prevention of Stroke, Systemic Embolism

11 de fev. de 2025, 06:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis: Anthos Is Developing Abelacimab, Currently in Late-Stage Trials

11 de fev. de 2025, 06:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis: Deal Is Expected to Close in 1H of 2025

11 de fev. de 2025, 06:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis Aims to Bolster Late-Stage Cardiovascular Pipeline With Acquisition

11 de fev. de 2025, 06:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis: Deal Includes Potential Additional Payments of Up to $2.15B

11 de fev. de 2025, 06:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis to Buy Anthos Therapeutics for $925M Upfront

11 de fev. de 2025, 06:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis to Buy Anthos Therapeutics

4 de fev. de 2025, 15:16 UTC

Principais Notícias

Novartis Sets High Bar in Pursuit of Obesity Deals, CEO Says -- Interview

4 de fev. de 2025, 08:12 UTC

Conversa de Mercado
Ganhos

Novartis Outlook Indicates No Patent Cliff Beyond 2025 -- Market Talk

31 de jan. de 2025, 13:56 UTC

Ganhos

Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker -- IBD

31 de jan. de 2025, 09:59 UTC

Ações em Alta

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

31 de jan. de 2025, 07:50 UTC

Conversa de Mercado

Novartis's Outlook Exceeds Market Views -- Market Talk

31 de jan. de 2025, 07:46 UTC

Conversa de Mercado
Ganhos

Novartis's Results Beat Could Clear Gap Between Mid-Term Outlook and Market Views -- Market Talk

31 de jan. de 2025, 06:03 UTC

Ganhos

Novartis Expects 2025 Core Operating Profit Growth of High Single to Low Double-Digit at Constant Currency

31 de jan. de 2025, 06:02 UTC

Ganhos

Novartis Expects 2025 Net Sales Growth of mid- to high-single Digit at Constant Currency

31 de jan. de 2025, 06:02 UTC

Ganhos

Novartis Issues 2025 View

31 de jan. de 2025, 06:02 UTC

Ganhos

Novartis Raises Dividend to CHF3.50 Vs CHF3.30

31 de jan. de 2025, 06:02 UTC

Ganhos

Novartis 4Q Oper Pft $3.53B

31 de jan. de 2025, 06:02 UTC

Ganhos

Novartis 4Q Net Pft $2.82B

31 de jan. de 2025, 06:02 UTC

Ganhos

Analysts Saw Novartis 4Q Core Operating Profit at $4.44B

31 de jan. de 2025, 06:02 UTC

Ganhos

Novartis 4Q Core Operating Profit $4.86B

Comparação entre Pares

Variação de preço

Novartis AG Previsão

Preço-alvo

By TipRanks

0.21% parte superior

Previsão para 12 meses

Média 111 USD  0.21%

Máximo 125 USD

Mínimo 97 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Novartis AG - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

2 ratings

0

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

109.97 / 112.06Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Strong Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.